Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors | NEJM Rezatapopt is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, which stabilizes p53 in its wild-type conformation and restores its f...

Rezatapopt for TP53 Y220C–Mutated Tumors. Game changer! #Y220C #Rezatapopt #PYNNACLE @nejm.org

Panel A: A figure showing the change in the sum of diameters of the target lesions across tumor types. Panel B: A figure showing the overall duration of treatment and the time to first response observed in 46 patients treated with a dose in the observed efficacious-dose range who had wild-type KRAS.

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: nej.md/3OIQC5P

#MedSky #Oncology

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators aacrjournals.org/cancerdisco...

Now in Cancer Discovery @aacrjournals.bsky.social: Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators - by @ferranfececruz.bsky.social, Andreas Varkaris, Aparna Parikh, Ryan Corcoran, et al. doi.org/10.1158/2159... @mgbresearch.bsky.social @harvardmed.bsky.social

Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators

aacrjournals.org/cancerdiscov...

Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today at Cancer Discovery @aacrjournals.bsky.social @mgbresearch.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social @oncodaily.bsky.social #CorcoranLab #Rezatapopt #PYNNACLE

Why biotech is booming in Barcelona World-class research institutes and university hospitals, a culture of groundbreaking science and a thriving investment ecosystem make Barcelona a rising star in the life sciences industry, as these t...

💯

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors Mutant-selective inhibitors of KRASG12C (KRASG12Ci) have demonstrated efficacy in KRASG12C cancers. However, resistance invariably develops, resulting in short-lived responses. We aimed to define the ...

⚠️ #CorcoranLab reports "Genomic landscape of clinically acquired resistance alterations in patients treated with #KRASG12C inhibitors", a work led by our brilliant Austrian postdoc Jakob Riedl! @mgbresearch.bsky.social @fwf-at.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social #crcsm #lcsm

After White House transition, FDA’s diversity guidance for clinical trials no longer available The FDA’s guidance detailing diversity action plans for clinical trials that evaluate drugs, devices and other medical products has been taken do | The FDA’s guidance detailing diversity action plans ...

I give up 🤦🏻‍♂️ #TheHandmaidsTale

Pan-RAS inhibitor RMC-6236 aka Daraxonrasib in patients with RAS-mutant pancreatic adenocarcinoma 🤯🤯🤯 #GI25
dailynews.ascopubs.org/do/pan-ras-i...

Phase 3 #BREAKWATER trial demonstrate a significantly improved response rate that was durable for first-line Encorafenib + Cetuximab + mFOLFOX6 vs. SOC in patients with BRAF V600E mCRC #crcsm #BRAF #GI25 @fightcrc.bsky.social
www.nature.com/articles/s41...

Site-saturation mutagenesis of 500 human protein domains - Nature Large-scale experimental analysis of Human Domainome 1, a library containing more than 500,000 missense mutation variants across more than 500 human protein domains, reveals that 60% of pathogenic mis...

🤯🤯🤯

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer Abstract. Purpose: Antibody-drug conjugates (ADCs) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer (MBC). However, knowledge of AD...

Incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in metastatic breast cancer, and the potential impact on mediating cross-resistance to sequential ADCs! @harvardmed.bsky.social @breastcancernow.bsky.social #CorcoranLab #bcsm #biomarkers #resistance

Great news! #RAS

Joan Guinovart, fundador de l'Institut de Recerca Biomèdica, s'ha mort a 77 anys Joan Guinovart, fundador i ex-director de l’Institut de Recerca Biomèdica de Barcelona (IRB), s’ha mort aquesta matinada a setanta-set anys, segons que ha informat l’IRB. Guinovart va néixer el 3 de j...

😢

Living the targeting #RAS era 🤯🤯🤯 #KRAS #G12C #G12D
www.cell.com/trends/cance...

Safety and efficacy of the next generation of PI3K targeting agents reviewed @sabcs.bsky.social #SABCS24 poster highlights PS7-01-02-03 @oncoalert.bsky.social

Great news fresh from #SABCS24 RLY-2608 (mutant selective PI3Kα inhibitor):
mPFS 9.2m (all patients)
mPFS 11.4m (for kinase domain mutants H1047R)
Clinical Benefit Rate 67%
#bcsm @breastcancernow.bsky.social

Why the genetic-testing revolution left some people behind — and what to do about it Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks are still too limited.

"Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks are still too limited."

Add me please 🙋🏻‍♂️

Oncology Combination Drug Development Strategies for Project Optimus Abstract. The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for s...

Interesting perspective on key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens @oncoalert.bsky.social #CancerTherapeutics #DrugDevelopment #Synergy

Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.

Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky

www.targetedonc.com/view/durvalu....

US academics: look after foreign students The first Trump term took a toll on international scholars and collaborations — we can avoid similar pitfalls.

"Although the policies of the incoming administration are not yet unsettled, fears and uncertainties can wreak damage on student morale. Check in with the foreign students/fellows in your classes, labs, and institutions." @harvardmed.bsky.social @aclum.bsky.social @academic-chatter.bsky.social

AstraZeneca pone el foco de su innovación en España El presidente de la farmacéutica en el país, Rick Suárez, pide reducir la burocracia para que los medicamentos lleguen antes a los pacientes

💪🏼💪🏼💪🏼
elpais.com/economia/neg...

Barcelona's Vall d'Hebron Hospital inaugurates a new facility that will host 1,000 researchers The new Vall d’Hebron Institute of Research (VHIR) has involved a €43 million investment.

🔬🧪🧫💪🏼
catalonia.com/w/barcelona-...

⬇️⬇️⬇️